✨ Medicines Distribution Consent




NEW ZEALAND GAZETTE, No. 26 β€” 19 MARCH 2015

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product:
Neostigmine Methylsulphate Injection

Active Ingredient:
Neostigmine metilsulfate 2.5mg/mL

Dosage Form:
Solution for injection

New Zealand Sponsor:
Max Health Limited

Manufacturer:
Hameln Pharmaceuticals GmbH, Hameln, Germany


Product:
Pomalyst

Active Ingredient:
Pomalidomide 1mg

Dosage Form:
Capsule

New Zealand Sponsor:
Celgene Limited

Manufacturers:
Celgene International Sarl, Boudry, Switzerland
Penn Pharmaceutical Services Limited, Gwent, United Kingdom


Product:
Pomalyst

Active Ingredient:
Pomalidomide 2mg

Dosage Form:
Capsule

New Zealand Sponsor:
Celgene Limited

Manufacturers:
Celgene International Sarl, Boudry, Switzerland
Penn Pharmaceutical Services Limited, Gwent, United Kingdom


Product:
Pomalyst

Active Ingredient:
Pomalidomide 3mg

Dosage Form:
Capsule

New Zealand Sponsor:
Celgene Limited

Manufacturers:
Celgene International Sarl, Boudry, Switzerland
Penn Pharmaceutical Services Limited, Gwent, United Kingdom


Product:
Pomalyst

Active Ingredient:
Pomalidomide 4mg

Dosage Form:
Capsule

New Zealand Sponsor:
Celgene Limited

Manufacturers:
Celgene International Sarl, Boudry, Switzerland
Penn Pharmaceutical Services Limited, Gwent, United Kingdom

Dated this 12th day of March 2015.

SARAH READER, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).

2015-go1552

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:

Schedule

Product:
Ilaris

Active Ingredient:
Canakinumab 150mg

Dosage Form:
Powder for injection

New Zealand Sponsor:
Novartis New Zealand Limited

Manufacturers:
Novartis Pharma Stein AG, Stein, Switzerland
Hameln Pharmaceuticals GmbH, Hameln, Germany

40



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2015, No 26





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
12 March 2015
Medicines, Distribution, Consent, Medicines Act 1981
  • SARAH READER, Acting Group Manager, Medsafe, Ministry of Health

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
12 March 2015
Medicines, Distribution, Consent, Medicines Act 1981
  • SARAH READER, Acting Group Manager, Medsafe, Ministry of Health